Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus DOXY 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus DOXY 100.
ACHROMYCIN vs DOXY 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic